摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene | 864070-38-2

中文名称
——
中文别名
——
英文名称
1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene
英文别名
1-chloro-4-(β-D-glucopyranosyl)-2-[4-(trifluoromethylsulphonyloxy)benzyl]benzene;1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulphonyloxy)-benzyl]-benzene;[4-[[2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]methyl]phenyl] trifluoromethanesulfonate
1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene化学式
CAS
864070-38-2
化学式
C20H20ClF3O8S
mdl
——
分子量
512.888
InChiKey
YESILICFESWAPS-FQBWVUSXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    648.2±55.0 °C(Predicted)
  • 密度:
    1.583±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    33
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    142
  • 氢给体数:
    4
  • 氢受体数:
    11

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene三甲基乙炔基硅 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 三乙胺甲醇potassium carbonate盐酸 作用下, 以 DMF (N,N-dimethyl-formamide) 、 甲醇 为溶剂, 反应 19.0h, 以40%的产率得到1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene
    参考文献:
    名称:
    [DE] GLUCOPYRANOSYL-SUBSTITUIERTE BENZOL-DERIVATE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
    [EN] GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
    [FR] DERIVES DU BENZOL SUBSTITUES PAR UN GLUCOPYRANOSYLE,, MEDICAMENTS RENFERMANT CES COMPOSES, LEUR UTILISATION ET LEUR PROCEDE DE PRODUCTION
    摘要:
    通用式(I)的葡萄糖吡喃基取代苯衍生物,其中残基R1至R6以及R7a、R7b、R7c如权利要求1所定义,包括它们的互变异构体、立体异构体、混合物和盐。这些化合物适用于治疗代谢疾病。
    公开号:
    WO2005092877A1
  • 作为产物:
    描述:
    依帕列净杂质N-苯基双(三氟甲烷磺酰)亚胺4-二甲氨基吡啶三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 4.0h, 以64%的产率得到1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene
    参考文献:
    名称:
    Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
    摘要:
    本发明涉及1-氯-4-(β-D-吡喃葡萄糖基-1-基)-2-(4-乙炔基苄基)苯的结晶水合物,以及1-氯-4-(β-D-吡喃葡萄糖基-1-基)-2-(4-乙炔基苄基)苯与天然氨基酸之间的结晶复合物,其制备方法,以及用于制备药物的应用。
    公开号:
    US20070054867A1
点击查看最新优质反应信息

文献信息

  • Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
    申请人:Eckhardt Matthias
    公开号:US20050209166A1
    公开(公告)日:2005-09-22
    Glucopyranosyl-substituted benzene derivatives of general formula I where the groups R 1 to R 6 as well as R 7a , R 7b , R 7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    通用公式I的葡萄糖吡喃基取代苯衍生物,其中R1至R6基团以及R7a、R7b、R7c在此定义,并且其互变异构体、立体异构体、混合物及盐。根据本发明的化合物适用于治疗代谢紊乱。
  • D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
    申请人:Eckhardt Matthias
    公开号:US20060009400A1
    公开(公告)日:2006-01-12
    A D-Xylopyranosyl-substituted phenyl compound of general formula I wherein the groups R 1 to R 5 , X, Z and R 7a , R 7b , R 7c are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention also relates to pharmaceutical compositions for the treatment of metabolic disorders.
    一般公式I中的A D-吡喃木糖基取代的苯基化合物 其中,R1至R5、X、Z以及R7a、R7b、R7c的定义如权利要求1所述,对钠依赖性葡萄糖共转运体SGLT具有抑制作用。本发明还涉及用于治疗代谢性疾病的药物组合物。
  • Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
    申请人:Himmelsbach Frank
    公开号:US20070004648A1
    公开(公告)日:2007-01-04
    Glucopyranosyloxy-substituted benzyl-benzene derivatives of the general formula I where the groups groups R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 , X and R 7a , R 7b , R 7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    根据权利要求1定义的通用公式I的葡萄糖吡喃氧基取代的苄基苯衍生物,包括基团R1、R2、R3a、R3b、R4、R5、R6、X以及R7a、R7b、R7c,包括互变异构体、立体异构体、它们的混合物以及它们的盐。根据发明的化合物适用于治疗代谢紊乱。
  • Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
    申请人:Himmelsbach Frank
    公开号:US20060189548A1
    公开(公告)日:2006-08-24
    Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives of the general formula I where the groups R 1 to R 6 as well as R 7a , R 7b , R 7c are defined according to claim 1 , including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    通用公式I的葡萄糖吡喃基取代的(杂)芳基乙炔基苯衍生物,其中基团R1至R6以及R7a、R7b、R7c根据权利要求1定义,包括其互变异构体、立体异构体、混合物及其盐。本发明的化合物适用于治疗代谢紊乱。
  • Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
    申请人:Himmelsbach Frank
    公开号:US20070027092A1
    公开(公告)日:2007-02-01
    Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives of the general formula I where the groups R 1 to R 6 as well as R 7a , R 7b , R 7c are defined according to claim 1 , including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    通用式I的葡萄糖吡喃基取代的((杂)环烷基乙炔基苄基)苯衍生物,其中基团R1至R6以及R7a、R7b、R7c根据权利要求1定义,包括其互变异构体、立体异构体、混合物及其盐。本发明的化合物适用于治疗代谢紊乱。
查看更多